Cetuximab, paclitaxel, carboplatin and radiation for esophageal and gastric cancer.

@article{Suntharalingam2006CetuximabPC,
  title={Cetuximab, paclitaxel, carboplatin and radiation for esophageal and gastric cancer.},
  author={Mohan Suntharalingam and Tom Dipetrillo and Paul A Akerman and Harold J. Wanebo and Barry David Daly and L. Austin Doyle and Mark Jonathan Krasna and Teresa A Kennedy and Howard P. Safran},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 18_suppl},
  pages={4029}
}
4029 Background: Cetuximab is an IgG1, chimerized, monoclonal antibody that binds specifically to the epidermal growth factor receptor. Cetuximab improves survival when combined with radiation for patients with locally advanced head and neck cancer. We evaluated the safety and efficacy of the addition of cetuximab to concurrent chemoradiation for patients with esophageal and gastric cancer. METHODS Patients with adenocarcinoma or squamous cell cancer of the esophagus or stomach without… CONTINUE READING